InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer’s disease (“AD”). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to comply with NASDAQ’s minimum bid price requirement for the continued listing on the NASDAQ Capital Market. InMed received a letter from the exchange notifying it of the extended … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer’s and age-related macular degeneration. Highlights … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held on Dec. 19, 2023, all matters considered by shareholders were approved; agenda items were … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting”
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today released financial results for the first quarter of the fiscal year 2024, which ended Sept. 30, 2023. “We are pleased with the continued advancements across our pharmaceutical programs and commercial operations. We are particularly … Continue reading “NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update”